A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant
Major Depression: Durability of Benefit Over a One-Year Follow-Up Period.
epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.
The efficacy and tolerability of levetiracetam in pharmacoresistant
Predicting the therapeutic response to cognitive behavioural therapy in patients with pharmacoresistant
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant
major depression: assessment of relapse during a 6-month, multisite, open-label study.
EpiMiRNA brings together experts on the neurobiology of miRNAs with the leading researchers working on miRNAs in epilepsy, epilepsy geneticists, leaders in miRNA-target detection, proteomics, and systems biology with research-intensive SMEs pursuing miRNA therapeutics and treatments for pharmacoresistant
Indicated for treatment of both pharmacoresistant
epilepsy and treatment-resistant depression (TRD), VNS Therapy consists of a pacemaker-like device implanted in the chest that delivers mild pulsed signals to the brain via the vagus nerve in the neck.
1] Engel estimated that as of the early 1990s more than 8000 patients had undergone a surgical procedure as the definitive treatment for pharmacoresistant
Recent research supports the notion that prolonged seizures become pharmacoresistant
if not treated promptly.
The newly selected candidates, similar in molecular structure to retigabine, have demonstrated much greater potency and potential efficacy in pre-clinical models, including a model of pharmacoresistant
There is an ongoing need for effective and well-tolerated treatment options for people with pharmacoresistant
epilepsy, particularly as many will try a range of drugs before finding one that works for them.
The results demonstrated that VNS Therapy improved Quality of Life and seizure rates compared to best medical management in patients with pharmacoresistant